News & Events – Sumitovant

Select Company

May 06, 2022Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension
May 02, 2022Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
April 25, 2022Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
September 13, 2021Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress
May 20, 2021Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study
May 06, 2021Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
April 26, 2021Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
April 21, 2021Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting
February 18, 2021Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
August 05, 2020Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH
1 2 3 Next »